Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
UAMC-3203 (UAMC3203) is a novel and selective Ferroptosis inhibitor with an IC50 value of 12 nM. It has anti-inflammatory and antioxidant properties. The radical-sequestering antioxidant Ferrostatin-1 (Fer-1) can prevent the iron-catalyzed, nonapoptotic form of controlled necrosis known as ferroptosis from damaging cell membranes. Novel inhibitors derived from the Fer-1 scaffold effectively inhibited ferroptosis but had solubility problems. After daily injections of UAMC-3203 for 4 weeks, no toxicity was seen in mice. In silico, UAMC-3203 inserts quickly into a phospholipid bilayer, which is consistent with the way these drugs currently work. In conclusion, these analogs are novel lead compounds with therapeutic potential in relevant ferroptosis-driven disease models. They exhibit in vivo efficacy, have better properties than Fer-1, and have superior properties to Fer-1.
Targets |
Ferroptosis (IC50 = 12 nM)
|
---|---|
ln Vitro |
UAMC-3203 has a remarkable t1/2 when incubated with human and rat microsomes (t1/2 = 20.5 h and t1/2 = 16.5 h, respectively), but it is discovered to be relatively less stable when incubated with murine microsomes (t1/2 = 3.46 h)[1].
|
ln Vivo |
UAMC-3203 significantly lowers the plasma levels of lactate dehydrogenase (LDH) in mice. As is typical for lipophilic basic compounds, it leaves the bloodstream quickly and is distributed again throughout the body's tissues. All of the tissues that were examined (liver, kidney, and lungs) contained significant levels of UAMC-3203[1].
|
References |
Molecular Formula |
C25H37N5O2S
|
---|---|
Molecular Weight |
471.6586
|
Exact Mass |
471.27
|
Elemental Analysis |
C, 63.66; H, 7.91; N, 14.85; O, 6.78; S, 6.80
|
CAS # |
2271358-64-4
|
Related CAS # |
UAMC-3203 hydrochloride;2271358-65-5
|
Appearance |
A solution in ethanol
|
SMILES |
C1CCC(CC1)NC2=C(C=C(C=C2)S(=O)(=O)NCCN3CCNCC3)NCC4=CC=CC=C4
|
InChi Key |
HSYSVXKJIVUNBR-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C25H37N5O2S/c31-33(32,28-15-18-30-16-13-26-14-17-30)23-11-12-24(29-22-9-5-2-6-10-22)25(19-23)27-20-21-7-3-1-4-8-21/h1,3-4,7-8,11-12,19,22,26-29H,2,5-6,9-10,13-18,20H2
|
Chemical Name |
3-(benzylamino)-4-(cyclohexylamino)-N-(2-piperazin-1-ylethyl)benzenesulfonamide
|
Synonyms |
UAMC-3203 free base; UAMC-3203; UAMC3203; UAMC 3203
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 94~250 mg/mL (199.3~530 mM)
Ethanol: ~94 mg/mL (~199.3 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1202 mL | 10.6009 mL | 21.2017 mL | |
5 mM | 0.4240 mL | 2.1202 mL | 4.2403 mL | |
10 mM | 0.2120 mL | 1.0601 mL | 2.1202 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.